V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 190010859 | 190008158 | 0 | 76 | Curative (C) | 2021-01-04 | 2021-01-26 | MAP | 01 | N | CISPLATIN + DOXORUBICIN + METHOTREXATE | 100146635 |
| 190010928 | 190008159 | 0 | 54 | Neo-adjuvant (N) | 2022-01-24 | 2022-02-06 | Docetaxel + Gemcitabine (prior RT) | 02 | N | DOCETAXEL + GEMCITABINE | 101391675 |
| 190000680 | 190008160 | 0 | 0 | null | 2016-11-23 | 2017-06-17 | METHOTREXATE | 02 | Y | METHOTREXATE | 101671483 |
| 190002742 | 190008161 | 1.77 | 81 | 03 | 2019-10-16 | 2019-10-16 | GEMCITABINE | 02 | N | CISPLATIN + CYTARABINE | 100678585 |
| 190007264 | 190008162 | 1.7 | null | Curative (C) | 2021-08-27 | 2021-08-27 | GemCarbo Days 1+8 | 02 | null | EURO-EWING | 101834705 |
| 190010127 | 190008163 | 0 | 67.8 | Palliative (P) | 2021-01-10 | 2021-08-10 | EW Rel Irinotecan & Temozolomide | null | null | CYCLOPHOSPHAMIDE + TOPOTECAN | 100767437 |
| 190009397 | 190008197 | 1.77 | 72.3 | null | 2016-08-17 | 2017-02-25 | Doxorubicin + Olaratumab | 2 | N | CISPLATIN + RT | 100097636 |
| 190009744 | 190008198 | 1.71 | 48.8 | Neo-adjuvant (N) | 2015-11-09 | 2016-07-26 | FLUOROURACIL + IRINOTECAN | N | N | CAPECITABINE + OXALIPLATIN | 100054242 |
| 190009768 | 190008199 | 1.69 | 62.6 | Curative (C) | null | 2022-05-15 | DHAP | null | null | LIPOSOMAL DOXORUBICIN | 101135474 |
| 190009824 | 190008200 | 1.7 | 78.6 | Palliative (P) | null | 2020-11-17 | CARBOPLATIN + RT | 02 | N | CARBOPLATIN | 101041721 |
| 190009878 | 190008201 | 1.63 | 94.1 | null | 2021-05-19 | 2021-05-20 | MAP | null | null | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | 100482626 |
| 190009897 | 190008202 | 1.95 | 45.1 | Palliative (P) | 2020-01-09 | 2020-01-26 | Cisplatin + Radiotherapy | 2 | N | CETUXIMAB + IRINOTECAN + MDG | 101513878 |
| 190009910 | 190008203 | null | 49.7 | Neo-adjuvant (N) | 2016-06-14 | 2016-06-14 | Atezolizumab | 02 | N | FLUOROURACIL + OXALIPLATIN | 101791109 |
| 190009950 | 190008204 | 1.59 | 80.9 | null | null | 2020-07-16 | Docetaxel 75mg/m2 (21 day) | null | null | ICON TRIAL | 100607227 |
| 190010002 | 190008205 | null | 85 | Curative (C) | 2020-04-22 | 2020-04-28 | Doxorubicin 75mg/m2 | null | null | DOXORUBICIN | 100064157 |
| 190010044 | 190008206 | 1.78 | 104 | Adjuvant (A) | 2022-04-23 | 2022-05-18 | Cyclophosphamide High Dose | 02 | Y | CISPLATIN + CYTARABINE | 101484428 |
| 190010117 | 190008208 | 1.75 | 22.6 | Disease modification (D) | 2021-03-28 | 2021-10-25 | OST Euramos 1 Closed Trial - IE | 02 | N | EW EUROEWING 2012 ARM A VIDE | 100494715 |
| 190010126 | 190008209 | 1.5 | 58.6 | Curative (C) | null | 2021-02-08 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | 02 | null | EURAMOS TRIAL | 100810176 |
| 190010254 | 190008210 | 0 | 105 | Palliative (P) | 2019-03-11 | 2019-05-30 | DOXORUBICIN + METHOTREXATE | 02 | null | IRINOTECAN + TEMOZOLOMIDE | 101655316 |
| 190010347 | 190008211 | 1.7 | 60.1 | Neo-adjuvant (N) | null | 2017-06-23 | Etoposide oral | 02 | N | DACTINOMYCIN + IFOSFAMIDE + VINCRISTINE | 100457965 |
| 190010358 | 190008212 | 0 | 53 | null | 2020-07-04 | 2020-10-03 | Folfirinox | 02 | null | EURAMOS TRIAL | 100958431 |
| 190010360 | 190008213 | 0 | 52.7 | null | 2021-06-12 | 2021-06-26 | OST Euramos 1 Closed Trial - A | 02 | null | OST A | 100086863 |
| 190010459 | 190008214 | 1.51 | 57.1 | Neo-adjuvant (N) | 2020-06-01 | 2020-06-06 | Trial Unspecified | 01 | Y | TRIAL UNSPECIFIED | 101317669 |
| 190010473 | 190008215 | 1.6 | 99.2 | Curative (C) | null | 2021-07-18 | Doxorubicin + Methotrexate | 02 | null | VAI | 100010762 |
| 190010554 | 190008216 | 1.73 | 53.2 | Adjuvant (A) | 2020-04-23 | 2020-04-23 | DOXORUBICIN | 02 | null | DOXORUBICIN | 101448429 |
| 190010596 | 190008217 | 0 | 41 | Curative (C) | 2020-11-13 | 2020-11-13 | OST Euramos 1 Closed Trial - A | 02 | N | OST A | 100167309 |
| 190010650 | 190008218 | 0 | 39.2 | Neo-adjuvant (N) | 2018-11-23 | 2018-12-17 | CAPECITABINE + TEMOZOLOMIDE | 02 | N | VIDE | 100561190 |
| 190010755 | 190008220 | 1.81 | 56 | Palliative (P) | 2019-09-06 | 2019-09-08 | METHOTREXATE | 02 | null | METHOTREXATE | 101847115 |
| 190010837 | 190008221 | 1.14 | 60 | Curative (C) | 2017-02-22 | 2019-11-29 | EURAMOS TRIAL | 02 | N | ETOPOSIDE | 101586453 |
| 190010853 | 190008222 | 0 | 55 | null | 2020-06-25 | 2020-12-13 | DOXORUBICIN | null | null | DOXORUBICIN | 100377460 |
| 190010859 | 190008223 | 0 | 56.1 | Neo-adjuvant (N) | 2021-01-23 | 2021-02-16 | EW EuroEwing 2012 Arm B VC | N | N | EW EUROEWING 2012 ARM B VC | 100146635 |
| 190010928 | 190008224 | 0.7 | 43 | Curative (C) | 2022-03-26 | 2022-04-01 | DOXORUBICIN | 02 | null | DOXORUBICIN | 101391675 |
| 190000680 | 190008225 | 0 | 58.6 | Curative (C) | 2017-06-30 | 2017-09-01 | OST Euramos 1 Closed Trial - M | 01 | N | IFOSFAMIDE | 101671483 |
| 190002742 | 190008226 | 0 | 43 | Neo-adjuvant (N) | 2019-08-16 | 2019-08-16 | Doxorubicin 75mg/m2 | 02 | Y | DOXORUBICIN | 100678585 |
| 190007264 | 190008227 | 1.07 | 45 | Curative (C) | 2021-07-16 | 2021-08-27 | NIVOLUMAB | 02 | null | CAV | 101834705 |
| 190003507 | 190008229 | null | null | null | null | 2019-07-10 | null | null | null | MIFAMURTIDE | 101115997 |
| 190009051 | 190008243 | 1.82 | 49.9 | null | 2021-03-28 | 2021-04-03 | Carboplatin + Paclitaxel (3 weekly) | 02 | N | CARBOPLATIN + PACLITAXEL | 100985989 |
| 190009397 | 190008245 | 0 | 68.2 | Palliative (P) | 2017-02-24 | 2017-02-25 | PEMBROLIZUMAB | 02 | N | CISPLATIN | 100097636 |
| 190009744 | 190008246 | 1.7 | 51.5 | null | 2016-05-27 | 2016-08-17 | EW EuroEwing 2012 Arm B VDC | 02 | N | LIPOSOMAL DOXORUBICIN | 100054242 |
| 190009768 | 190008247 | 1.58 | 132.1 | Palliative (P) | 2022-05-18 | 2022-05-29 | Trial Unspecified | 02 | N | TRIAL UNSPECIFIED | 101135474 |
| 190009824 | 190008248 | 1.76 | 74 | null | 2021-01-15 | 2021-01-16 | CAPECITABINE + IRINOTECAN | 02 | N | LIPOSOMAL DOXORUBICIN | 101041721 |
| 190009878 | 190008249 | 1.89 | 48.4 | null | 2020-06-24 | 2021-06-21 | EW EuroEwing 2012 Arm B VDC | 02 | N | OST REL IFOSFAMIDE ETOPOSIDE | 100482626 |
| 190009897 | 190008250 | null | 67.2 | null | 2020-01-13 | 2020-01-26 | null | 02 | N | IFOSFAMIDE | 101513878 |
| 190009910 | 190008251 | null | 75.3 | 03 | 2016-01-24 | 2016-07-01 | DOXORUBICIN | N | N | DOXORUBICIN | 101791109 |
| 190010117 | 190008254 | 1.79 | 47.2 | Neo-adjuvant (N) | 2021-09-07 | 2021-10-25 | EW EuroEwing 2012 Arm A VAC | null | null | NOT MATCHED | 100494715 |
| 190010254 | 190008255 | 1.76 | 29.5 | Curative (C) | 2018-01-28 | 2019-06-15 | IRINOTECAN + MDG + PANITUMUMAB | 02 | N | DACTINOMYCIN + IFOSFAMIDE + VINCRISTINE | 101655316 |
| 190010347 | 190008256 | 1.71 | 63.3 | null | 2017-07-14 | 2017-08-13 | Methotrexate High Dose (3g/m2) | 02 | N | METHOTREXATE | 100457965 |
| 190010358 | 190008257 | 1.47 | 22.5 | null | 2020-08-02 | 2020-10-25 | Carboplatin + Etoposide iv&po | null | null | DACTINOMYCIN + IFOSFAMIDE + VINCRISTINE | 100958431 |
| 190010459 | 190008258 | 1.75 | 81.25 | Neo-adjuvant (N) | null | 2020-06-12 | OST Euramos 1 Closed Trial - A | 02 | N | OST A | 101317669 |
| 190010554 | 190008259 | 0 | 62.8 | Palliative (P) | 2021-04-22 | 2021-05-04 | Doxorubin 50mg/m2 | 02 | null | DOXORUBICIN | 101448429 |